Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate
At the World Parkinson Congress 2016 in Portland earlier today, Anavex Life Sciences (NASDAQ: AVXL) presented preclinical data in a poster titled “Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease.” Initial data demonstrated that the company’s ANAVEX 2-73, a sigma-1 receptor agonist, restores function in … Continue reading “Anavex Life Sciences Corp. (AVXL) Presents Positive Initial Data for Parkinson’s Disease Drug Candidate”
